Carcinoma in situ of anus and anal canal (controls excluding all cancers)

CD2_INSITU_ANUS_ANAL_EXALLC

No definition available.

Endpoint definition

FinnGen phenotype data

individuals

diagram downward connector

Apply sex-specific rule None

diagram downward connector
diagram bullet

Check conditions

not C3_ANUS_ANALCANAL

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, registry filters

Hospital Discharge: ICD-10 D01.3&
Hospital discharge: ICD-9 230[5-6]
Cause of death: ICD-10 D01.3&
Cause of death: ICD-9 230[5-6]
Cancer registry: Topography ICD-O-3 C21
Cancer registry: Morphology ICD-O-3 ANY
Cancer registry: Behaviour codes 2

3 out of 7 registries used, show all original rules.

-

diagram downward connector

Check minimum number of events None

-

diagram downward connector

Include endpoints None

-

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

16

diagram downward connector
CD2_INSITU_ANUS_ANAL_EXALLC

Control definitions

Control exclude C3_CANCER, C3_CANCER_WIDE

Extra metadata

Level in the ICD hierarchy 3
First used in FinnGen datafreeze DF9
Parent code in ICD-10 D01
Name in latin Carcinoma in situ laryngis

Similar endpoints

List of similar endpoints to Carcinoma in situ of anus and anal canal (controls excluding all cancers) based on the number of shared cases.

Venn diagram with an highlighted set fully inside another set Broader endpoints:

Venn diagram with a set fully inside an highlighted set Narrower endpoints:

Show all endpoint correlations

Summary Statistics

Key figures

All Female Male
Number of individuals 16 12 -
Unadjusted prevalence (%) 0.00 0.01 -
Mean age at first event (years) 64.01 62.38 -

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 - - - -
15 years - - - -
5 years - - - -
1 year - - - -

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

Index endpoint: CD2_INSITU_ANUS_ANAL_EXALLC – Carcinoma in situ of anus and anal canal (controls excluding all cancers)
GWS hits:

Survival analyses between endpoints

Not a core endpoint, no data to show.

Drugs most likely to be purchased after Carcinoma in situ of anus and anal canal (controls excluding all cancers)

Endpoint not on priority list, no data to show.